Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dasatinib + peginterferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Norwegian University of Science and Technology
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Dasatinib + peginterferon alfa-2b is an investigational combination therapy being evaluated for the treatment of newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP). The regimen combines dasatinib, a potent second-generation tyrosine kinase inhibitor (TKI) that targets the BCR-ABL1 oncoprotein, with peginterferon alfa-2b, a pegylated form of interferon-alpha with immunomodulatory and antiproliferative properties. This combination aims to eradicate leukemic stem cells and restore anti-CML immunity, potentially leading to deeper molecular responses and higher rates of treatment-free remission (TFR) compared to TKI monotherapy. It has been primarily studied in the NordCML007 Phase 2 trial sponsored by the Norwegian University of Science and Technology (NTNU) on behalf of the Nordic CML Study Group.
- Other names
- dasatinib + peginterferondasatinib + PegIFN-α2bdasatinib + pegylated interferon-α2b
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)CSF1R (Macrophage colony-stimulating factor receptor)DDR1/2 (Discoidin domain-containing receptor 1 (DDR1) and Discoidin domain-containing receptor 2 (DDR2))EPH (EPH receptor family)FGFR1 (Fibroblast growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)TEC family (TEC family tyrosine kinases)IFNAR (Immune system modulation via type I interferon receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)SRC (Proto-oncogene tyrosine-protein kinase Src)
Beyond the preview
Go deeper on dasatinib + peginterferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dasatinib + peginterferon alfa-2b.